July 2018
Volume 59, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2018
Intraocular pressure reduction effects of Ripasudil after Trabectome® surgery
Author Affiliations & Notes
  • Yuta Saito
    Ophthalmology, Showa University, Tokyo, TOKYO, Japan
  • Chiaki Yui
    Ophthalmology, Showa University, Tokyo, TOKYO, Japan
  • Kensaku Yasuda
    Ophthalmology, Showa University, Tokyo, TOKYO, Japan
  • Eiko Miura
    Ophthalmology, Showa University, Tokyo, TOKYO, Japan
  • Noriko Yasuda
    Ophthalmology, Showa University, Tokyo, TOKYO, Japan
  • Haruo Takahashi
    Ophthalmology, Showa University, Tokyo, TOKYO, Japan
  • Footnotes
    Commercial Relationships   Yuta Saito, None; Chiaki Yui, None; Kensaku Yasuda, None; Eiko Miura, None; Noriko Yasuda, None; Haruo Takahashi, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 1230. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Yuta Saito, Chiaki Yui, Kensaku Yasuda, Eiko Miura, Noriko Yasuda, Haruo Takahashi; Intraocular pressure reduction effects of Ripasudil after Trabectome® surgery. Invest. Ophthalmol. Vis. Sci. 2018;59(9):1230. doi: https://doi.org/.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose : Ripasudil ophthalmic solution, which is one of ROCK inhibitors, is considered to act on the trabecular meshwork (TM) and have an effect of promoting conventional aqueous humor outflow. In addition, Trabectome® promotes aqueous outflow to the episcleral veins by ablation of the TM to partially opening of Schlemm’s canal. Hence, the mechanism of intraocular pressure (IOP) reducing between Ripasudil and Trabectome® is overlap. In this study, we investigated the IOP reduction effects by Ripasudil before and after Trabectome® surgery.

Methods : Observational study. Nine eyes of 8 patients with primary open-angle glaucoma (POAG) or pseudoexfoliation glaucoma (EXG) treated with Ripasudil ophthalmic solution suitable for Trabectome® were included. The patients had not previously undergone surgery except for cataract surgery. All surgery was performed from July 2017 to October at Showa University Hospital by one surgeon with Trabectome®. IOP before and after 2 hours treating with Ripasudil 0.4% ophthalmic solution was measured at before surgery, 1 week and 1 month after surgery. After surgery, glaucoma instillation other than Ripasudil was resumed at the discretion of the surgeon. Statistical analyses were performed with paired t test. P value <0.05 was considered significantly.

Results : The relevant data of the study cases is shown in Table 1. Preoperatively, IOP (mmHg) before instillation with Ripasudil was 22.6 ± 6.4, reducing significantly to 20.9 ± 5.5 after 2 hours (p<0.01). IOP before and after instillation was 17.0 ± 5.6, 16.9 ± 5.2 (p = 0.94) at 1 week, and 21.2 ± 8.2, 22.4 ± 9.9 (p = 0.14) at 1 month after surgery, respectively. Number of eye drops was 4.8 ± 0.8 before surgery, reducing to 2.4 ± 1.4 at 1 week and 2.4 ± 1.4 at 1 mouth after surgery, respectively.

Conclusions : The effects of Ripasudil to reduce IOP may attenuate after Trabectome®. However, the number of patients is small, and the IOP value is greatly scattered in this study. More number of cases is needed to evaluate the effect of Ripasudil after Trabectome®.

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.



This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.